What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent

References

1. 1.↵
   2. Lu M,
   3. Cohen MH,
   4. Rieves D, et al

   . FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 2010;85:315–19 doi:10.1002/ajh.21656 pmid:20201089

   CrossRefPubMed
2. 2.↵
   2. Bashir MR,
   3. Bhatti L,
   4. Marin D, et al

   . Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging 2015;41:884–98 doi:10.1002/jmri.24691 pmid:24974785

   CrossRefPubMed
3. 3.↵
   2. Hope MD,
   3. Hope TA,
   4. Zhu C, et al

   . Vascular imaging with ferumoxytol as a contrast agent. AJR Am J Roentgenol 2015;205:W366–73 doi:10.2214/AJR.15.14534 pmid:26102308

   CrossRefPubMed
4. 4.↵
   2. Nayak AB,
   3. Luhar A,
   4. Hanudel M, et al

   . High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. Pediatr Nephrol 2015;30:515–21 doi:10.1007/s00467-014-2953-x pmid:25212105

   CrossRefPubMed
5. 5.↵
   2. Varallyay CG,
   3. Nesbit E,
   4. Fu R, et al

   . High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle. J Cereb Blood Flow Metab 2013;33:780–86 doi:10.1038/jcbfm.2013.36 pmid:23486297

   CrossRefPubMed
6. 6.↵
   2. Christen T,
   3. Ni W,
   4. Qiu D, et al

   . High-resolution cerebral blood volume imaging in humans using the blood pool contrast agent ferumoxytol. Magn Reson Med 2013;70:705–10 doi:10.1002/mrm.24500 pmid:23001902

   CrossRefPubMed
7. 7.↵
   2. Finn JP,
   3. Nguyen KL,
   4. Han F, et al

   . Cardiovascular MRI with ferumoxytol. Clin Radiol 2016;71:796–806 doi:10.1016/j.crad.2016.03.020 pmid:27221526

   CrossRefPubMed
8. 8.↵
   2. Neuwelt EA,
   3. Hamilton BE,
   4. Varallyay CG, et al

   . Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int 2009;75:465–74 doi:10.1038/ki.2008.496 pmid:18843256

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Neuwelt EA,
   3. Várallyay CG,
   4. Manninger S, et al

   . The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 2007;60:601–11; discussion 611–12 doi:10.1227/01.NEU.0000255350.71700.37 pmid:17415196

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Storey P,
    3. Arbini AA

    . Bone marrow uptake of ferumoxytol: a preliminary study in healthy human subjects. J Magn Reson Imaging 2014;39:1401–10 doi:10.1002/jmri.24320 pmid:24123697

    CrossRefPubMed
11. 11.↵
    2. Guthrie PJ,
    3. Thomas JV,
    4. Peker D, et al

    . Perivesical unicentric Castleman disease initially suspected to be metastatic prostate cancer. Urol Ann 2016;8:245–48 doi:10.4103/0974-7796.177196 pmid:27141204

    CrossRefPubMed
12. 12.↵
    2. Liu L,
    3. Tseng L,
    4. Ye Q, et al

    . A new method for preparing mesenchymal stem cells and labeling with ferumoxytol for cell tracking by MRI. Sci Rep 2016;6:26271 doi:10.1038/srep26271 pmid:27188664

    CrossRefPubMed
13. 13.↵
    2. Pouw JJ,
    3. Grootendorst MR,
    4. Bezooijen R, et al

    . Pre-operative sentinel lymph node localization in breast cancer with superparamagnetic iron oxide MRI: the SentiMAG Multicentre Trial imaging subprotocol. Br J Radiol 2015;88:20150634 doi:10.1259/bjr.20150634 pmid:26492466

    CrossRefPubMed
14. 14.↵
    2. Wang YX

    . Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging. World J Gastroenterol 2015;21:13400–02 doi:10.3748/wjg.v21.i47.13400 pmid:26715826

    CrossRefPubMed
15. 15.↵
    2. Muehe AM,
    3. Feng D,
    4. von Eyben R, et al

    . Safety report of ferumoxytol for magnetic resonance imaging in children and young adults. Invest Radiol 2016;51:221–27 doi:10.1097/RLI.0000000000000230 pmid:26656202

    CrossRefPubMed
16. 16.↵
    2. Vasanawala SS,
    3. Nguyen KL,
    4. Hope MD, et al

    . Safety and technique of ferumoxytol administration for MRI. Magn Reson Med 2016;75:2107–11 doi:10.1002/mrm.26151 pmid:26890830

    CrossRefPubMed
17. 17.↵
    2. Nguyen KL,
    3. Yoshida T,
    4. Han F, et al

    . MRI with ferumoxytol: a single center experience of safety across the age spectrum. J Magn Res Imaging 2017;45:804–12 doi:10.1002/jmri.25412 pmid:27480885

    CrossRefPubMed
18. 18.↵
    Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Published August 9, 2006. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed April 3, 2017.
19. 19.↵
    Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published 2010. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed April 3, 2017.
20. 20.↵
    What is a serious adverse event? U.S. Food and Drug Administration. https://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm. Accessed May 4, 2017.
21. 21.↵
    2. Brockow K,
    3. Sánchez-Borges M

    . Hypersensitivity to contrast media and dyes. Immunol Allergy Clin North Am 2014;34:547–64, viii doi:10.1016/j.iac.2014.04.002 pmid:25017677

    CrossRefPubMed
22. 22.↵
    2. Vadhan-Raj S,
    3. Strauss W,
    4. Ford D, et al

    . Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol 2014;89:7–12 doi:10.1002/ajh.23582 pmid:23983177

    CrossRefPubMed
23. 23.↵
    2. Macdougall IC,
    3. Strauss WE,
    4. McLaughlin J, et al

    . A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol 2014;9:705–12 doi:10.2215/CJN.05320513 pmid:24458078

    Abstract/FREE Full Text
24. 24.↵
    2. Hetzel D,
    3. Strauss W,
    4. Bernard K, et al

    . A phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol 2014;89:646–50 doi:10.1002/ajh.23712 pmid:24639149

    CrossRefPubMed
25. 25.↵
    2. Bleicher AG,
    3. Kanal E

    . Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. AJR Am J Roentgenol 2008;191:W307–11 doi:10.2214/AJR.07.3951 pmid:19020220

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Katayama H,
    3. Yamaguchi K,
    4. Kozuka T, et al

    . Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990;175:621–28 doi:10.1148/radiology.175.3.2343107 pmid:2343107

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Evans C,
    3. Dalgleish AG,
    4. Kumar D

    . Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther 2006;24:1163–77 doi:10.1111/j.1365-2036.2006.03075.x pmid:17014575

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Kawakami Y,
    3. Yaguchi T,
    4. Sumimoto H, et al

    . Cancer-induced immunosuppressive cascades and their reversal by molecular-targeted therapy. Ann N Y Acad Sci 2013;1284:80–86 doi:10.1111/nyas.12094 pmid:23651199

    CrossRefPubMed
29. 29.↵
    2. Pumhirun P,
    3. Wasuwat P

    . Anergy testing in patients with head and neck cancer. Asian Pac J Allergy Immunol 2003;21:189–92 pmid:15032403

    PubMed
30. 30.↵
    2. Braaten K,
    3. Holcombe RF,
    4. Kim SS

    . Premedication with IV steroids effectively prevented anaphylactic reactions following ferumoxytol given as IV push in hematology and oncology patients. Am J Hematol 2015;90:E207 doi:10.1002/ajh.24132 pmid:26257099

    CrossRefPubMed
31. 31.↵
    2. Bircher AJ,
    3. Auerbach M

    . Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am 2014;34:707–23, x–xi doi:10.1016/j.iac.2014.04.013 pmid:25017687

    CrossRefPubMed
32. 32.↵
    2. Rampton D,
    3. Folkersen J,
    4. Fishbane S, et al

    . Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014;99:1671–76 doi:10.3324/haematol.2014.111492 pmid:25420283

    Abstract/FREE Full Text
33. 33.↵
    2. Gahramanov S,
    3. Muldoon LL,
    4. Varallyay CG, et al

    . Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. Radiology 2013;266:842–52 doi:10.1148/radiol.12111472 pmid:23204544

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Kanda T,
    3. Ishii K,
    4. Kawaguchi H, et al

    . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

    CrossRefPubMed
35. 35.
    2. Gahramanov S,
    3. Raslan AM,
    4. Muldoon LL, et al

    . Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Incol Biol Phys 2011;79:514–23 doi:10.1016/j.ijrobp.2009.10.072 pmid:20395065

    CrossRefPubMed
36. 36.
    2. Hamilton BE,
    3. Nesbit GM,
    4. Dosa E, et al

    . Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. AJR Am J Roentgenol 2011;197:981–88 doi:10.2214/AJR.10.5992 pmid:21940589

    CrossRefPubMed
37. 37.
    2. Nasseri M,
    3. Gahramanov S,
    4. Netto JP, et al

    . Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. Neuro Oncol 2014;16:1146–54 doi:10.1093/neuonc/not328 pmid:24523362

    Abstract/FREE Full Text
38. 38.
    2. Dósa E,
    3. Tuladhar S,
    4. Muldoon LL, et al

    . MRI using ferumoxytol improves the visualization of central nervous system vascular malformations. Stroke 2011;42:1581–88 doi:10.1161/STROKEAHA.110.607994 pmid:21493906

    Abstract/FREE Full Text
39. 39.
    2. Dósa E,
    3. Guillaume DJ,
    4. Haluska M, et al

    . Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol. Neuro Oncol 2011;13:251–60 doi:10.1093/neuonc/noq172 pmid:21163809

    Abstract/FREE Full Text
40. 40.
    2. Farrell BT,
    3. Hamilton BE,
    4. Dósa E, et al

    . Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL. Neurology 2013;81:256–63 doi:10.1212/WNL.0b013e31829bfd8f pmid:23771486

    Abstract/FREE Full Text
41. 41.
    2. Hamilton BE,
    3. Woltjer RL,
    4. Prola-Netto J, et al

    . Ferumoxytol-enhanced MRI differentiation of meningioma from dural metastases: a pilot study with immunohistochemical observations. J Neurooncol 2016;129:301–09 doi:10.1007/s11060-016-2175-0 pmid:27393348

    CrossRefPubMed
42. 42.
    2. Thompson EM,
    3. Guillaume DJ,
    4. Dósa E, et al

    . Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. J Neurooncol 2012;109:105–14 doi:10.1007/s11060-012-0872-x pmid:22528798

    CrossRefPubMed
43. 43.
    UpToDate: Evidence-Based Clinical Decision Support System. Waltham, Massachusetts: Wolters Kluwer; 1992 [updated in 2016]. https://www.uptodate.com. Accessed April 3, 2017.
44. 44.
    ACR Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.2. Published June 2016. https://www.acr.org/∼/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast-Manual/2016_Contrast_Media.pdf. Accessed April 3, 2017.